Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Arthritis Rheum. 2010 Aug;62(8):2382–2391. doi: 10.1002/art.27550

Figure 5.

Figure 5

Urinary CTXII (uCTXII) levels, normalized to creatinine, of untreated ACL transected joints (ACLT, n=6), PBS-treated (PBS, n=6), HSL-treated (HSL, n=3), rhPRG4 treated (rhPRG4, n=6) and HSFL-treated (HSFL, n=6) animals on days 17 and 29 post-injury. *Indicates that day 17 uCTXII levels of HSL and HSFL-treated animals were significantly lower than corresponding uCTXII levels of untreated (p=0.005; p=0.002) and PBS-treated (p=0.002; p<0.001) animals, respectively. **Indicates that day 29 uCTXII levels of HSFL-treated animals were significantly lower (p<0.001) than PBS-treated animals.